Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer

Research output: Contribution to journalArticle

Abstract

Chemotherapy has been combined with therapeutic tumor-specific vaccination in an attempt to simultaneously debulk tumors, increase the effector lymphocyte:tumor cell ratio, and favor immune-mediated tumor rejection. However, chemotherapy is often inadequate because of insufficient and uneven drug penetration into tumors, and because it might also cause, in some instances, undesirable side effects and immunosuppression. Here, we suggest a combined approach based on targeted alteration of the endothelial barrier function with vascular disrupting agents, such as tumor necrosis factor-α (TNF-α), before chemotherapy and tumor-specific vaccination. This approach has the potential to empower chemoimmunotherapeutic strategies by improving cytotoxic drug penetration into tumors while exploiting the proinflammatory and immunostimulating activities of TNF-α and active immunotherapy.

Original languageEnglish
Pages (from-to)235-241
Number of pages7
JournalTrends in Immunology
Volume29
Issue number5
DOIs
Publication statusPublished - May 2008

Fingerprint

Active Immunotherapy
Blood Vessels
Drug Therapy
Neoplasms
Vaccination
Tumor Necrosis Factor-alpha
Pharmaceutical Preparations
Immunosuppression
Lymphocytes

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

@article{e508987f2ba04e31b9c2350293755630,
title = "Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer",
abstract = "Chemotherapy has been combined with therapeutic tumor-specific vaccination in an attempt to simultaneously debulk tumors, increase the effector lymphocyte:tumor cell ratio, and favor immune-mediated tumor rejection. However, chemotherapy is often inadequate because of insufficient and uneven drug penetration into tumors, and because it might also cause, in some instances, undesirable side effects and immunosuppression. Here, we suggest a combined approach based on targeted alteration of the endothelial barrier function with vascular disrupting agents, such as tumor necrosis factor-α (TNF-α), before chemotherapy and tumor-specific vaccination. This approach has the potential to empower chemoimmunotherapeutic strategies by improving cytotoxic drug penetration into tumors while exploiting the proinflammatory and immunostimulating activities of TNF-α and active immunotherapy.",
author = "Matteo Bellone and Anna Mondino and Angelo Corti",
year = "2008",
month = "5",
doi = "10.1016/j.it.2008.02.003",
language = "English",
volume = "29",
pages = "235--241",
journal = "Trends in Immunology",
issn = "1471-4906",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Vascular targeting, chemotherapy and active immunotherapy

T2 - teaming up to attack cancer

AU - Bellone, Matteo

AU - Mondino, Anna

AU - Corti, Angelo

PY - 2008/5

Y1 - 2008/5

N2 - Chemotherapy has been combined with therapeutic tumor-specific vaccination in an attempt to simultaneously debulk tumors, increase the effector lymphocyte:tumor cell ratio, and favor immune-mediated tumor rejection. However, chemotherapy is often inadequate because of insufficient and uneven drug penetration into tumors, and because it might also cause, in some instances, undesirable side effects and immunosuppression. Here, we suggest a combined approach based on targeted alteration of the endothelial barrier function with vascular disrupting agents, such as tumor necrosis factor-α (TNF-α), before chemotherapy and tumor-specific vaccination. This approach has the potential to empower chemoimmunotherapeutic strategies by improving cytotoxic drug penetration into tumors while exploiting the proinflammatory and immunostimulating activities of TNF-α and active immunotherapy.

AB - Chemotherapy has been combined with therapeutic tumor-specific vaccination in an attempt to simultaneously debulk tumors, increase the effector lymphocyte:tumor cell ratio, and favor immune-mediated tumor rejection. However, chemotherapy is often inadequate because of insufficient and uneven drug penetration into tumors, and because it might also cause, in some instances, undesirable side effects and immunosuppression. Here, we suggest a combined approach based on targeted alteration of the endothelial barrier function with vascular disrupting agents, such as tumor necrosis factor-α (TNF-α), before chemotherapy and tumor-specific vaccination. This approach has the potential to empower chemoimmunotherapeutic strategies by improving cytotoxic drug penetration into tumors while exploiting the proinflammatory and immunostimulating activities of TNF-α and active immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=42749085280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42749085280&partnerID=8YFLogxK

U2 - 10.1016/j.it.2008.02.003

DO - 10.1016/j.it.2008.02.003

M3 - Article

C2 - 18375183

AN - SCOPUS:42749085280

VL - 29

SP - 235

EP - 241

JO - Trends in Immunology

JF - Trends in Immunology

SN - 1471-4906

IS - 5

ER -